Abstract
BackgroundPatients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have